The Swiss pharma company Novartis ranks in the top 10 of pharma companies, and boasts drugs ranging from Ritalin and Lamisil to clozapine, Diovan and Gilenya. It also owns the generic giant Sandoz. Unlike its competitor, GlaxoSmithKline, Novartis did not offer free flu vaccines during the H1N1 flu epidemic.

In March 2011, Novartis gained FDA approval for Gilenya, its multiple sclerosis drug. The nod came on the heels of a narrower EMA approval, which grants second-line treatment status. According to experts, the drug could be worth $3 billion in annual sales as the first oral MS drug on the market.

Novartis purchased the remaining portion of eye care company Alcon in a $12.9 billion deal at the end of 2010, marking the end of one of the biggest battles in biopharma. Although many analysts predicted heavy layoffs in 2010 from the company, only 1,400 jobs were cut in December 2010, with the disclaimer that more could be on the way as Novartis, like others in the industry, analyzes its efficiency.

Tag:

Novartis

Latest Headlines

Latest Headlines

Lilly, Novartis and Pfizer join with Broad Institute for bioinformatics challenge

A clutch of Big Pharma companies is backing a competition to create predictive models that could lead to new targets for cancer drugs. Eli Lilly, Novartis and Pfizer are among the data funders of the competition, which calls for the development of models that show how essential a gene is to the survival of a cancer cell.

Novartis nabs Merck exec Bruno Strigini to head up oncology business

Novartis wooed one of Merck & Co.'s top executives to take the helm at its oncology unit.

District judge green-lights kickback lawsuit against Novartis

Novartis has to face a kickbacks lawsuit filed by the U.S. Department of Justice, which alleges that the Swiss drugmaker gave pharmacies discounts and rebates to boost sales of two drugs, a federal judge ruled Thursday.

Investigator database looking for new members after adding Novartis and Pfizer to ranks

Having made the big decisions about how their database of clinical trial investigators will work, collaborators Eli Lilly, Merck and Johnson & Johnson are looking to add more members to a roster already swelled by the arrival of Novartis and Pfizer.

GSK India exec sees growth fueled by Novartis vaccine assets

GlaxoSmithKline's emerging-market vaccines sales have seen better days, thanks to a $489 million bribery probe that recently led to the indictment of the company's former China head. But according to a local exec, good times are ahead for Glaxo's vaccines unit in India--and the company's recent pickup of Novartis' non-flu vaccine assets will help it get there.

GlaxoSmithKline's India unit eyes sales growth after Novartis vax deal

According to a local exec, good times are ahead for Glaxo's vaccines unit in India--and the company's recent pickup of Novartis' non-flu vaccine assets will help it get there.

Roche, Novartis face $1.6B in damages on Italy's Lucentis collusion ruling

Three months ago, antitrust authorities in Italy fined Novartis and Roche $251 million on charges they colluded to protect sales of their eye drug, Lucentis. Now, that country's Health Ministry is seeking further damages.

Top 10 best-selling vaccines of 2013

The vaccine market has long been dominated by the Big 3--Sanofi, Merck and GlaxoSmithKline--with Pfizer and Novartis trailing the trio on the list of revenue-generators. But things are changing at the top.

The EU's not impressed with Novartis' 'breakthrough' cardio drug, either

After an FDA rejection and an earlier negative opinion, Novartis' cardio treatment serelaxin has again failed to sway European regulators, and the drugmaker has resigned that its breakthrough-designated therapy will not hit any market this year.

Novartis, Boehringer vie for COPD market share with combo meds

Rivals Novartis and Boehringer Ingelheim are touting positive results for their combination COPD treatments, duking it out with GlaxoSmithKline for dominance of a market that could reach $14 billion by 2018.